Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Fimasartan/Amlodipine/Rosuvastatin FDC vs Co-administration
NCT02569814Phase 1Completed
- Sponsor
- Boryung
- Start
- Sep 2015
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fimasartan, amlodipine and rosuvastatin in hypertension (HTN) and hyperlipidemia (2 arms), sponsored by Boryung. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the last measurable concentration. Started Sep 2015; status: completed.
02
Drugs
fimasartanamlodipinerosuvastatin
03
Conditions
hypertension (HTN)hyperlipidemia
Beyond the preview
Go deeper on NCT02569814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02569814.